"Companion diagnostics": has their time come and gone?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).Clinical lung cancer · 2021
   Trial
2. Up-regulation by overexpression of c-MET in fibroblastic foci of usual interstitial pneumonia.Pathologica · 2023
   Article
3. Changes in Companion Diagnostic Labelling: Implementation of FDA's April 2020 Guidance for Industry for In Vitro CDx Labeling for Specific Oncology Therapeutic Groups.Therapeutic innovation & regulatory science · 2022
   Review
4. An appraisal of drug development timelines in the Era of precision oncology.Oncotarget · 2016
   Article
5. PD-L1 testing, fit for routine evaluation? From a pathologist's point of view.Memo · 2016
   Review
6. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.Cancer gene therapy · 2015
   Review
7. Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein.Acta neuropathologica · 2015
   Article
8. Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.Molecular oncology · 2015
   Review

Corrections and comments

• Comment on
  Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.2014

Authors and funding

3 authors.

Funding

Abstract

Indexed as